^
Association details:
| Biomarker: | KRAS G12V |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Vectibix (panitumumab) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
PD-0025 Evaluation of Codon 12 and 13 KRAS Mutations as Biomarkers of Response to Panitumumab in Patients with Metastatic Colorectal Cancer
Excerpt:
MT KRAS alleles were significantly associated with outcomes by interaction testing: in the panitumumab + FOLFOX4 arm of study 20050203 G12V was favorably and G13D was unfavorably associated with OS.
Secondary therapy:
FOLFOX4
DOI:
10.1016/S0923-7534(20)30001-6
Source:
Title:
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Excerpt:
CONTRADICTING EVIDENCE: The treatment effect on PFS in the wild-type (WT) KRAS group (hazard ratio [HR], 0.45; 95% CI: 0.34 to 0.59) was significantly greater (P < .0001) than in the mutant group (HR, 0.99; 95% CI, 0.73 to 1.36). Median PFS in the WT KRAS group was 12.3 weeks for panitumumab and 7.3 weeks for BSC. Response rates to panitumumab were 17% and 0%, for the WT and mutant groups, respectively. WT KRAS patients had longer overall survival (HR, 0.67; 95% CI, 0.55 to 0.82; treatment arms combined)....Table 2. Distribution of KRAS Mutations By Treatment Arm.
DOI:
10.1200/JCO.2007.14.7116
